Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance study

ObjectivesTo monitor the safety and utilisation of AZD1222 under real-world use in the UK.DesignA non-interventional post-authorisation active surveillance study.SettingVaccination sites in the UK.ParticipantsA total of 17 945 participants were eligible and provided consent to participate in the stu...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	BMJ open Ročník 15; číslo 5; s. e093366
Hlavní autori:	Evans, Alison, Roy, Debabrata, Davies, Miranda, Dhanda, Sandeep, Morris, Denise, Aurelius, Taylor, Lane, Samantha, Fry, Catherine, Shakir, Saad
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England British Medical Journal Publishing Group 02.05.2025 BMJ Publishing Group LTD BMJ Publishing Group
Predmet:	Adult Aged Breastfeeding & lactation ChAdOx1 nCoV-19 - adverse effects Clinical medicine COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects Drug Utilization Epidemiology Family physicians Female Headache - chemically induced Headache - epidemiology Humans Immunization Male Middle Aged Non-pharmacological intervention Original Research Pandemics Product Surveillance, Postmarketing Public health Regulatory agencies Safety SARS-CoV-2 Surveillance United Kingdom - epidemiology Vaccination United Kingdom United Kingdom > UK Drug Utilization Vaccination Safety
ISSN:	2044-6055, 2044-6055
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	ObjectivesTo monitor the safety and utilisation of AZD1222 under real-world use in the UK.DesignA non-interventional post-authorisation active surveillance study.SettingVaccination sites in the UK.ParticipantsA total of 17 945 participants were eligible and provided consent to participate in the study between 1 March 2021 and 6 April 2023. Participants were followed up at weeks 1, 4 and 14 and at months 6, 9, 12 and 18 after the first dose of AZD1222 vaccination and prompted to complete electronic data capture forms. A total of 11 219 participants submitted a Follow-Up 1 form and 5189 participants submitted a Follow-Up 7 form (at 18 months).Primary and secondary outcome measuresThe safety of AZD1222, including the identification, assessment and quantification of serious adverse events (SAEs) and adverse events of special interest (AESI), was examined. The utilisation of AZD1222 was described and characterised, including populations with missing information.ResultsThe majority of participants were women (n=10 845; 60.4%) and the median age (IQR) was 50 (43, 62) years. Most participants were from white ethnic groups (n=13 112; 73.1%). Headache and fatigue had the highest reported incidence rate (421.28 cases per 1000 person years and 386.00 cases per 1000 person years, respectively). The most frequently reported AESI was anosmia (6.25 cases per 1000 person years). An increased Observed versus Expected (O:E) ratio was seen for anaphylaxis (O:E 7.38 (95% CI 2.80 to 11.95); based on 10 observed cases (expected cases: 1.36)) and anosmia and/or ageusia (O:E 39.23 (95% CI 29.13 to 49.32), based on 58 observed cases (expected cases: 1.48)).ConclusionsThe most frequent vaccinee-reported adverse events (AEs) were headache and fatigue. An increased O:E ratio was seen for the AEs of anaphylaxis and anosmia and/or ageusia. No safety signals were identified throughout the course of this study.Trial registration numberThis study is registered with the HMA-EMA Catalogue of RWD studies (EUPAS44035).
AbstractList	ObjectivesTo monitor the safety and utilisation of AZD1222 under real-world use in the UK.DesignA non-interventional post-authorisation active surveillance study.SettingVaccination sites in the UK.ParticipantsA total of 17 945 participants were eligible and provided consent to participate in the study between 1 March 2021 and 6 April 2023. Participants were followed up at weeks 1, 4 and 14 and at months 6, 9, 12 and 18 after the first dose of AZD1222 vaccination and prompted to complete electronic data capture forms. A total of 11 219 participants submitted a Follow-Up 1 form and 5189 participants submitted a Follow-Up 7 form (at 18 months).Primary and secondary outcome measuresThe safety of AZD1222, including the identification, assessment and quantification of serious adverse events (SAEs) and adverse events of special interest (AESI), was examined. The utilisation of AZD1222 was described and characterised, including populations with missing information.ResultsThe majority of participants were women (n=10 845; 60.4%) and the median age (IQR) was 50 (43, 62) years. Most participants were from white ethnic groups (n=13 112; 73.1%). Headache and fatigue had the highest reported incidence rate (421.28 cases per 1000 person years and 386.00 cases per 1000 person years, respectively). The most frequently reported AESI was anosmia (6.25 cases per 1000 person years). An increased Observed versus Expected (O:E) ratio was seen for anaphylaxis (O:E 7.38 (95% CI 2.80 to 11.95); based on 10 observed cases (expected cases: 1.36)) and anosmia and/or ageusia (O:E 39.23 (95% CI 29.13 to 49.32), based on 58 observed cases (expected cases: 1.48)).ConclusionsThe most frequent vaccinee-reported adverse events (AEs) were headache and fatigue. An increased O:E ratio was seen for the AEs of anaphylaxis and anosmia and/or ageusia. No safety signals were identified throughout the course of this study.Trial registration numberThis study is registered with the HMA-EMA Catalogue of RWD studies (EUPAS44035). To monitor the safety and utilisation of AZD1222 under real-world use in the UK. A non-interventional post-authorisation active surveillance study. Vaccination sites in the UK. A total of 17 945 participants were eligible and provided consent to participate in the study between 1 March 2021 and 6 April 2023. Participants were followed up at weeks 1, 4 and 14 and at months 6, 9, 12 and 18 after the first dose of AZD1222 vaccination and prompted to complete electronic data capture forms. A total of 11 219 participants submitted a Follow-Up 1 form and 5189 participants submitted a Follow-Up 7 form (at 18 months). The safety of AZD1222, including the identification, assessment and quantification of serious adverse events (SAEs) and adverse events of special interest (AESI), was examined. The utilisation of AZD1222 was described and characterised, including populations with missing information. The majority of participants were women (n=10 845; 60.4%) and the median age (IQR) was 50 (43, 62) years. Most participants were from white ethnic groups (n=13 112; 73.1%). Headache and fatigue had the highest reported incidence rate (421.28 cases per 1000 person years and 386.00 cases per 1000 person years, respectively). The most frequently reported AESI was anosmia (6.25 cases per 1000 person years). An increased Observed versus Expected (O:E) ratio was seen for anaphylaxis (O:E 7.38 (95% CI 2.80 to 11.95); based on 10 observed cases (expected cases: 1.36)) and anosmia and/or ageusia (O:E 39.23 (95% CI 29.13 to 49.32), based on 58 observed cases (expected cases: 1.48)). The most frequent vaccinee-reported adverse events (AEs) were headache and fatigue. An increased O:E ratio was seen for the AEs of anaphylaxis and anosmia and/or ageusia. No safety signals were identified throughout the course of this study. This study is registered with the HMA-EMA Catalogue of RWD studies (EUPAS44035). To monitor the safety and utilisation of AZD1222 under real-world use in the UK.OBJECTIVESTo monitor the safety and utilisation of AZD1222 under real-world use in the UK.A non-interventional post-authorisation active surveillance study.DESIGNA non-interventional post-authorisation active surveillance study.Vaccination sites in the UK.SETTINGVaccination sites in the UK.A total of 17 945 participants were eligible and provided consent to participate in the study between 1 March 2021 and 6 April 2023. Participants were followed up at weeks 1, 4 and 14 and at months 6, 9, 12 and 18 after the first dose of AZD1222 vaccination and prompted to complete electronic data capture forms. A total of 11 219 participants submitted a Follow-Up 1 form and 5189 participants submitted a Follow-Up 7 form (at 18 months).PARTICIPANTSA total of 17 945 participants were eligible and provided consent to participate in the study between 1 March 2021 and 6 April 2023. Participants were followed up at weeks 1, 4 and 14 and at months 6, 9, 12 and 18 after the first dose of AZD1222 vaccination and prompted to complete electronic data capture forms. A total of 11 219 participants submitted a Follow-Up 1 form and 5189 participants submitted a Follow-Up 7 form (at 18 months).The safety of AZD1222, including the identification, assessment and quantification of serious adverse events (SAEs) and adverse events of special interest (AESI), was examined. The utilisation of AZD1222 was described and characterised, including populations with missing information.PRIMARY AND SECONDARY OUTCOME MEASURESThe safety of AZD1222, including the identification, assessment and quantification of serious adverse events (SAEs) and adverse events of special interest (AESI), was examined. The utilisation of AZD1222 was described and characterised, including populations with missing information.The majority of participants were women (n=10 845; 60.4%) and the median age (IQR) was 50 (43, 62) years. Most participants were from white ethnic groups (n=13 112; 73.1%). Headache and fatigue had the highest reported incidence rate (421.28 cases per 1000 person years and 386.00 cases per 1000 person years, respectively). The most frequently reported AESI was anosmia (6.25 cases per 1000 person years). An increased Observed versus Expected (O:E) ratio was seen for anaphylaxis (O:E 7.38 (95% CI 2.80 to 11.95); based on 10 observed cases (expected cases: 1.36)) and anosmia and/or ageusia (O:E 39.23 (95% CI 29.13 to 49.32), based on 58 observed cases (expected cases: 1.48)).RESULTSThe majority of participants were women (n=10 845; 60.4%) and the median age (IQR) was 50 (43, 62) years. Most participants were from white ethnic groups (n=13 112; 73.1%). Headache and fatigue had the highest reported incidence rate (421.28 cases per 1000 person years and 386.00 cases per 1000 person years, respectively). The most frequently reported AESI was anosmia (6.25 cases per 1000 person years). An increased Observed versus Expected (O:E) ratio was seen for anaphylaxis (O:E 7.38 (95% CI 2.80 to 11.95); based on 10 observed cases (expected cases: 1.36)) and anosmia and/or ageusia (O:E 39.23 (95% CI 29.13 to 49.32), based on 58 observed cases (expected cases: 1.48)).The most frequent vaccinee-reported adverse events (AEs) were headache and fatigue. An increased O:E ratio was seen for the AEs of anaphylaxis and anosmia and/or ageusia. No safety signals were identified throughout the course of this study.CONCLUSIONSThe most frequent vaccinee-reported adverse events (AEs) were headache and fatigue. An increased O:E ratio was seen for the AEs of anaphylaxis and anosmia and/or ageusia. No safety signals were identified throughout the course of this study.This study is registered with the HMA-EMA Catalogue of RWD studies (EUPAS44035).TRIAL REGISTRATION NUMBERThis study is registered with the HMA-EMA Catalogue of RWD studies (EUPAS44035). Objectives To monitor the safety and utilisation of AZD1222 under real-world use in the UK.Design A non-interventional post-authorisation active surveillance study.Setting Vaccination sites in the UK.Participants A total of 17 945 participants were eligible and provided consent to participate in the study between 1 March 2021 and 6 April 2023. Participants were followed up at weeks 1, 4 and 14 and at months 6, 9, 12 and 18 after the first dose of AZD1222 vaccination and prompted to complete electronic data capture forms. A total of 11 219 participants submitted a Follow-Up 1 form and 5189 participants submitted a Follow-Up 7 form (at 18 months).Primary and secondary outcome measures The safety of AZD1222, including the identification, assessment and quantification of serious adverse events (SAEs) and adverse events of special interest (AESI), was examined. The utilisation of AZD1222 was described and characterised, including populations with missing information.Results The majority of participants were women (n=10 845; 60.4%) and the median age (IQR) was 50 (43, 62) years. Most participants were from white ethnic groups (n=13 112; 73.1%). Headache and fatigue had the highest reported incidence rate (421.28 cases per 1000 person years and 386.00 cases per 1000 person years, respectively). The most frequently reported AESI was anosmia (6.25 cases per 1000 person years). An increased Observed versus Expected (O:E) ratio was seen for anaphylaxis (O:E 7.38 (95% CI 2.80 to 11.95); based on 10 observed cases (expected cases: 1.36)) and anosmia and/or ageusia (O:E 39.23 (95% CI 29.13 to 49.32), based on 58 observed cases (expected cases: 1.48)).Conclusions The most frequent vaccinee-reported adverse events (AEs) were headache and fatigue. An increased O:E ratio was seen for the AEs of anaphylaxis and anosmia and/or ageusia. No safety signals were identified throughout the course of this study.Trial registration number This study is registered with the HMA-EMA Catalogue of RWD studies (EUPAS44035).
Author	Lane, Samantha Morris, Denise Roy, Debabrata Davies, Miranda Aurelius, Taylor Fry, Catherine Evans, Alison Dhanda, Sandeep Shakir, Saad
Author_xml	– sequence: 1 givenname: Alison orcidid: 0000-0003-1878-2429 surname: Evans fullname: Evans, Alison email: alison.evans@dsru.org organization: University of Portsmouth, Portsmouth, UK – sequence: 2 givenname: Debabrata orcidid: 0000-0003-2803-6323 surname: Roy fullname: Roy, Debabrata organization: University of Portsmouth, Portsmouth, UK – sequence: 3 givenname: Miranda orcidid: 0000-0003-2949-8378 surname: Davies fullname: Davies, Miranda organization: University of Portsmouth, Portsmouth, UK – sequence: 4 givenname: Sandeep surname: Dhanda fullname: Dhanda, Sandeep organization: University of Portsmouth, Portsmouth, UK – sequence: 5 givenname: Denise surname: Morris fullname: Morris, Denise organization: University of Portsmouth, Portsmouth, UK – sequence: 6 givenname: Taylor surname: Aurelius fullname: Aurelius, Taylor organization: University of Portsmouth, Portsmouth, UK – sequence: 7 givenname: Samantha orcidid: 0000-0001-7532-1149 surname: Lane fullname: Lane, Samantha organization: University of Portsmouth, Portsmouth, UK – sequence: 8 givenname: Catherine orcidid: 0000-0002-5307-1297 surname: Fry fullname: Fry, Catherine organization: University of Portsmouth, Portsmouth, UK – sequence: 9 givenname: Saad surname: Shakir fullname: Shakir, Saad organization: University of Portsmouth, Portsmouth, UK
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/40316343$$D View this record in MEDLINE/PubMed
BookMark	eNp9Uk1vEzEUtFARbUN_ARKyxKUclvrZXu-aC4pSPiIq5QDtgYtle72No8067HpD8-9xmgTaHuqLn_1mRqP35hQdtaF1CL0B8gGAiQuzXISVazNKKM-IZEyIF-iEEs4zQfL86EF9jM76fkHS4bnMc_oKHXPCQDDOTtCfH7p2cYN1W-Eh-sb3OvrQ4lDj8a9LoJTi88l8XM3uALeTcJOBfI8ns5vpZarwWlvrW_cRa3z9Ha9CHzM9xHnoDjLaRr92uB-6tfNNo1ubHnGoNq_Ry1o3vTvb3yN0_eXzz8m37Gr2dToZX2Um5zRmhaZADBPSgCgLU7rCVSVwp_OSklxIIoFrBlUpiTCW1aYuQDJaalFWkoNjIzTd6VZBL9Sq80vdbVTQXt1_hO5W6S562zhleWV0IYvKcss51KYEyZmhJQABIVjS-rTTWg1m6Srr2tjp5pHo407r5-o2rBWkXUiZ5j1C53uFLvweXB_V0vfWbQfjwtArBlKWnFMmE_TdE-giDF2bZqUYJVDkPOdb1NuHlv55OSw4AeQOYLvQ952rlfXxfjfJoW8UELXNk9rnSW3zpHZ5Slz2hHuQf551sWOl5n_PzzH-ApR921s
CitedBy_id	crossref_primary_10_1016_j_vaccine_2025_127597 crossref_primary_10_1007_s40264_025_01579_w crossref_primary_10_1007_s40278_025_82285_4
Cites_doi	10.1136/bmj.n1114 10.1016/j.vaccine.2022.11.031 10.1136/bmjopen-2020-045343 10.1007/s13577-021-00512-4 10.1136/jnnp.2005.073221 10.1136/bmj.n513 10.1093/ije/dyv098 10.1016/j.vaccine.2022.08.007 10.1016/S1473-3099(21)00404-7 10.1002/jmv.28771 10.1016/j.eclinm.2019.10.001 10.3399/bjgp13X668456 10.1016/j.jclinepi.2007.11.008 10.1177/014107680409701204 10.1136/bmjebm-2020-111507 10.1002/9781444300710 10.1258/jrsm.97.12.571
ContentType	Journal Article
Copyright	Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. 2025 Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. 2025
Copyright_xml	– notice: Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. – notice: 2025 Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. 2025
DBID	9YT ACMMV AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 88G 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR BTHHO CCPQU COVID DWQXO FYUFA GHDGH GNUQQ K9- K9. KB0 M0R M0S M1P M2M NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM DOA
DOI	10.1136/bmjopen-2024-093366
DatabaseName	BMJ Open Access Journals BMJ Journals:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central BMJ Journals ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Consumer Health Database (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database ProQuest Health & Medical Collection Medical Database Psychology Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition BMJ Journals ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Public Health
EISSN	2044-6055
ExternalDocumentID	oai_doaj_org_article_c4dba797dc4c441fb81943b281101663 PMC12049934 40316343 10_1136_bmjopen_2024_093366 bmjopen
Genre	Journal Article
GeographicLocations	United Kingdom United Kingdom--UK
GeographicLocations_xml	– name: United Kingdom – name: United Kingdom--UK
GrantInformation_xml	– fundername: AstraZeneca UK grantid: EUPAS44035 funderid: http://dx.doi.org/10.13039/100031315 – fundername: ; grantid: EUPAS44035
GroupedDBID	--- 4.4 53G 5VS 7RV 7X7 7~R 88E 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV AENEX AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BKNYI BPHCQ BTFSW BTHHO CCPQU DIK DWQXO EBS FYUFA GNUQQ GROUPED_DOAJ GX1 HMCUK HYE HZ~ K9- KQ8 M0R M1P M2M M~E NAPCQ O9- OK1 PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PSYQQ RHI RMJ RPM UKHRP AAYXX ADRAZ AFFHD BVXVI CITATION EJD H13 M48 PJZUB PPXIY CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK COVID K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-b542t-7a210b369b1687b8e7ed814ea58205690914a31d8906bc3fbf719328a68d941e3
IEDL.DBID	DOA
ISICitedReferencesCount	2
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001481009000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2044-6055
IngestDate	Mon Nov 10 04:34:40 EST 2025 Tue Nov 04 02:03:32 EST 2025 Fri Sep 05 17:15:56 EDT 2025 Mon Nov 10 11:11:01 EST 2025 Thu May 08 05:30:49 EDT 2025 Sat Nov 29 07:37:15 EST 2025 Tue Nov 18 22:29:48 EST 2025 Thu May 08 14:20:30 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	Drug Utilization Vaccination Safety
Language	English
License	This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-b542t-7a210b369b1687b8e7ed814ea58205690914a31d8906bc3fbf719328a68d941e3
Notes	Original research ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 The Drug Safety Research Unit (DSRU) is an independent academic institution which works in association with the University of Portsmouth. All authors have no competing interest to declare. This study (EUPAS44035) was conducted with support from AstraZeneca UK Limited. Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
ORCID	0000-0003-2949-8378 0000-0003-1878-2429 0000-0002-5307-1297 0000-0003-2803-6323 0000-0001-7532-1149
OpenAccessLink	https://doaj.org/article/c4dba797dc4c441fb81943b281101663
PMID	40316343
PQID	3201754549
PQPubID	2040975
ParticipantIDs	doaj_primary_oai_doaj_org_article_c4dba797dc4c441fb81943b281101663 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12049934 proquest_miscellaneous_3199844239 proquest_journals_3201754549 pubmed_primary_40316343 crossref_citationtrail_10_1136_bmjopen_2024_093366 crossref_primary_10_1136_bmjopen_2024_093366 bmj_journals_10_1136_bmjopen_2024_093366
PublicationCentury	2000
PublicationDate	2025-05-02
PublicationDateYYYYMMDD	2025-05-02
PublicationDate_xml	– month: 05 year: 2025 text: 2025-05-02 day: 02
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR
PublicationTitle	BMJ open
PublicationTitleAbbrev	BMJ Open
PublicationTitleAlternate	BMJ Open
PublicationYear	2025
Publisher	British Medical Journal Publishing Group BMJ Publishing Group LTD BMJ Publishing Group
Publisher_xml	– name: British Medical Journal Publishing Group – name: BMJ Publishing Group LTD – name: BMJ Publishing Group
References	Willame, Dodd, Durán (R18) 2023; 41 Redwood, Gill (R24) 2013; 63 Moynihan, Sanders, Michaleff (R19) 2021; 11 Dhanda, Osborne, Lynn (R3) 2022; 27 Gallagher, Thomas, Hamilton (R16) 2004; 97 Latinovic, Gulliford, Ridsdale (R15) 2006; 77 Laffan, Rees, Yadavalli (R17) 2022; 40 Kadambari, Vanderslott (R26) 2021; 21 Watson, Caster, Rochon (R22) 2019; 17 Kashte, Gulbake, El-Amin Iii (R2) 2021; 34 Pottegård, Lund, Karlstad (R9) 2021; 373 Razai, Osama, McKechnie (R25) 2021; 372 Herrett, Gallagher, Bhaskaran (R27) 2015; 44 von Elm, Altman, Egger (R10) 2008; 61 Riad, Schulz-Weidner, Dziedzic (R20) 2023; 95 Watson (2025081404365665000_15.5.e093366.22) 2019; 17 2025081404365665000_15.5.e093366.27 2025081404365665000_15.5.e093366.21 2025081404365665000_15.5.e093366.24 2025081404365665000_15.5.e093366.23 2025081404365665000_15.5.e093366.4 2025081404365665000_15.5.e093366.3 Kashte (2025081404365665000_15.5.e093366.2) 2021; 34 2025081404365665000_15.5.e093366.1 2025081404365665000_15.5.e093366.8 2025081404365665000_15.5.e093366.7 2025081404365665000_15.5.e093366.6 2025081404365665000_15.5.e093366.5 Riad (2025081404365665000_15.5.e093366.20) 2023; 95 Laffan (2025081404365665000_15.5.e093366.17) 2022; 40 Razai (2025081404365665000_15.5.e093366.25) 2021; 372 2025081404365665000_15.5.e093366.15 2025081404365665000_15.5.e093366.14 Willame (2025081404365665000_15.5.e093366.18) 2023; 41 2025081404365665000_15.5.e093366.16 2025081404365665000_15.5.e093366.11 2025081404365665000_15.5.e093366.10 2025081404365665000_15.5.e093366.13 2025081404365665000_15.5.e093366.12 Moynihan (2025081404365665000_15.5.e093366.19) 2021; 11 Kadambari (2025081404365665000_15.5.e093366.26) 2021; 21 Pottegård (2025081404365665000_15.5.e093366.9) 2021; 373
References_xml	– volume: 373 year: 2021 ident: R9 article-title: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study publication-title: BMJ doi: 10.1136/bmj.n1114 – volume: 41 start-page: 251 year: 2023 ident: R18 article-title: Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study publication-title: Vaccine (Auckl) doi: 10.1016/j.vaccine.2022.11.031 – volume: 11 year: 2021 ident: R19 article-title: Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review publication-title: BMJ Open doi: 10.1136/bmjopen-2020-045343 – volume: 34 start-page: 711 year: 2021 ident: R2 article-title: COVID-19 vaccines: rapid development, implications, challenges and future prospects publication-title: Hum Cell doi: 10.1007/s13577-021-00512-4 – volume: 77 start-page: 385 year: 2006 ident: R15 article-title: Headache and migraine in primary care: consultation, prescription, and referral rates in a large population publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp.2005.073221 – volume: 372 year: 2021 ident: R25 article-title: Covid-19 vaccine hesitancy among ethnic minority groups publication-title: BMJ doi: 10.1136/bmj.n513 – volume: 44 start-page: 827 year: 2015 ident: R27 article-title: Data Resource Profile: Clinical Practice Research Datalink (CPRD) publication-title: Int J Epidemiol doi: 10.1093/ije/dyv098 – volume: 40 start-page: 5585 year: 2022 ident: R17 article-title: Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations publication-title: Vaccine (Auckl) doi: 10.1016/j.vaccine.2022.08.007 – volume: 21 start-page: 1204 year: 2021 ident: R26 article-title: Lessons about COVID-19 vaccine hesitancy among minority ethnic people in the UK publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00404-7 – volume: 95 year: 2023 ident: R20 article-title: Oral side effects of COVID-19 vaccines in 32 European countries: Analysis of EudraVigilance reports publication-title: J Med Virol doi: 10.1002/jmv.28771 – volume: 17 year: 2019 ident: R22 article-title: Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2019.10.001 – volume: 63 start-page: 342 year: 2013 ident: R24 article-title: Under-representation of minority ethnic groups in research--call for action publication-title: Br J Gen Pract doi: 10.3399/bjgp13X668456 – volume: 61 start-page: 344 year: 2008 ident: R10 article-title: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2007.11.008 – volume: 97 start-page: 571 year: 2004 ident: R16 article-title: Incidence of fatigue symptoms and diagnoses presenting in UK primary care from 1990 to 2001 publication-title: J R Soc Med doi: 10.1177/014107680409701204 – volume: 27 start-page: 1 year: 2022 ident: R3 article-title: Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK? publication-title: BMJ Evid Based Med doi: 10.1136/bmjebm-2020-111507 – ident: 2025081404365665000_15.5.e093366.1 – ident: 2025081404365665000_15.5.e093366.8 doi: 10.1002/9781444300710 – ident: 2025081404365665000_15.5.e093366.10 doi: 10.1016/j.jclinepi.2007.11.008 – volume: 17 year: 2019 ident: 2025081404365665000_15.5.e093366.22 article-title: Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2019.10.001 – volume: 40 start-page: 5585 year: 2022 ident: 2025081404365665000_15.5.e093366.17 article-title: Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations publication-title: Vaccine (Auckl) doi: 10.1016/j.vaccine.2022.08.007 – ident: 2025081404365665000_15.5.e093366.12 – ident: 2025081404365665000_15.5.e093366.5 – ident: 2025081404365665000_15.5.e093366.14 – volume: 11 year: 2021 ident: 2025081404365665000_15.5.e093366.19 article-title: Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review publication-title: BMJ Open doi: 10.1136/bmjopen-2020-045343 – volume: 95 year: 2023 ident: 2025081404365665000_15.5.e093366.20 article-title: Oral side effects of COVID-19 vaccines in 32 European countries: Analysis of EudraVigilance reports publication-title: J Med Virol doi: 10.1002/jmv.28771 – ident: 2025081404365665000_15.5.e093366.24 doi: 10.3399/bjgp13X668456 – ident: 2025081404365665000_15.5.e093366.15 doi: 10.1136/jnnp.2005.073221 – ident: 2025081404365665000_15.5.e093366.21 – volume: 373 year: 2021 ident: 2025081404365665000_15.5.e093366.9 article-title: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study publication-title: BMJ doi: 10.1136/bmj.n1114 – ident: 2025081404365665000_15.5.e093366.23 – ident: 2025081404365665000_15.5.e093366.16 doi: 10.1258/jrsm.97.12.571 – ident: 2025081404365665000_15.5.e093366.11 – ident: 2025081404365665000_15.5.e093366.4 – ident: 2025081404365665000_15.5.e093366.13 – ident: 2025081404365665000_15.5.e093366.6 – volume: 372 year: 2021 ident: 2025081404365665000_15.5.e093366.25 article-title: Covid-19 vaccine hesitancy among ethnic minority groups publication-title: BMJ doi: 10.1136/bmj.n513 – ident: 2025081404365665000_15.5.e093366.3 doi: 10.1136/bmjebm-2020-111507 – ident: 2025081404365665000_15.5.e093366.27 doi: 10.1093/ije/dyv098 – ident: 2025081404365665000_15.5.e093366.7 – volume: 21 start-page: 1204 year: 2021 ident: 2025081404365665000_15.5.e093366.26 article-title: Lessons about COVID-19 vaccine hesitancy among minority ethnic people in the UK publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00404-7 – volume: 34 start-page: 711 year: 2021 ident: 2025081404365665000_15.5.e093366.2 article-title: COVID-19 vaccines: rapid development, implications, challenges and future prospects publication-title: Hum Cell doi: 10.1007/s13577-021-00512-4 – volume: 41 start-page: 251 year: 2023 ident: 2025081404365665000_15.5.e093366.18 article-title: Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study publication-title: Vaccine (Auckl) doi: 10.1016/j.vaccine.2022.11.031
SSID	ssj0000459552
Score	2.3984423
Snippet	ObjectivesTo monitor the safety and utilisation of AZD1222 under real-world use in the UK.DesignA non-interventional post-authorisation active surveillance... To monitor the safety and utilisation of AZD1222 under real-world use in the UK. A non-interventional post-authorisation active surveillance study. Vaccination... To monitor the safety and utilisation of AZD1222 under real-world use in the UK.OBJECTIVESTo monitor the safety and utilisation of AZD1222 under real-world use... Objectives To monitor the safety and utilisation of AZD1222 under real-world use in the UK.Design A non-interventional post-authorisation active surveillance...
SourceID	doaj pubmedcentral proquest pubmed crossref bmj
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	e093366
SubjectTerms	Adult Aged Breastfeeding & lactation ChAdOx1 nCoV-19 - adverse effects Clinical medicine COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects Drug Utilization Epidemiology Family physicians Female Headache - chemically induced Headache - epidemiology Humans Immunization Male Middle Aged Non-pharmacological intervention Original Research Pandemics Product Surveillance, Postmarketing Public health Regulatory agencies Safety SARS-CoV-2 Surveillance United Kingdom - epidemiology Vaccination
SummonAdditionalLinks	– databaseName: BMJ Journals dbid: RMJ link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB61BVV94T4CBRmJhyKR7jp2nJi3ZUvFobYIaFX1JbITh23VJtVudoF_z0wuWIQqxFOixHF8fM5849jfADxHI2EznobYAzL1Za5y30qX-xnZRh1aNJlxHWwi2t-Pj4_1xxXg3V4Ye3FGYaO28djsaCCNpqIa8HAQDhy530pt08z0Klwj14aA_GnvfT-tggxFh3WcHXy59JGsh63WEBeqyx0LFki_yWwD1iUCWwnat7OKCZYMVK3j_zfy-ecayt-M0u7N_6jOLbjRMlA2aiBzG1ZccQfW99p_7Hfh22eTu-oHM0XGEJXn7XofVuZsdLLD0dKzrfFklB1856wYl0c-1y_Y-ODo3Q6esYVJKZtXzLDDD-yynFW-mVeTctplY-oPLJvNpwtHEY8QdKzWuL0Hh7tvvozf-m14Bt-GMqj8yKC7aIXSlqs4srGLXBZz6UyIrCJEr1tzaQTHXh8qm4rc5hGxxdioONOSO3Ef1oqycA-Baau405mRWqYyyJU1VhhpzZDn8VDYyIMtbMGkHV6zpPZchEra5k2oP5OmNT0Iuu5L0lbmnKJtnF_90Mv-octG5ePq5K8JF31SkuiuL5TTr0k74pNUZtZEOspSrJPkuUXuJYUNYk4TJkp4sNmh6lfFBPKxCEmt1B4862_jiKffOKZw5RzT0LZIScKNHjxoQNiXpIOyB_ESPJeKunynOJ3UquI8IO9XyEf_3taPYSOgcMi0_jPYhLVqOndP4Hq6qE5n06f1wPwJOMUyNQ priority: 102 providerName: BMJ Publishing Group Ltd – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLZYhxAS4jJuhYGMxMOQiFbHJ07MC-q6TSBENwGbJl4iO3Ho0EhKmxb495yTuB1FqC-8RY5t2Tpfzs3Odxh7jkbC5iKLUAKQBVCoIrDgiiAn26gjiyYzaYpNxMNhcnamj33CbeqvVS50YqOo8yqjHPmuREsVo7kH_Xr8PaCqUXS66ktobLBNYiqDDtvcOxgef1hmWdBh0VEUerohIdWu_faV6lLh2kIIKJwnfsQNbF0xTA1__7-czr_vTv5hjA5v_e82brOb3g3l_RY3d9gVV26xa-_9QfsWu9Gm83j7l9Jd9uOjKVz9i5sy5wjVC38JiFcF73_eF2j--c5g1M-PfgpeDqrTQOgXfHB0-nYfn_jcZDTtK274yTs-rqZ1YGb1qJospjGN1uXT2WTuqAwSIpE3xLf32MnhwafBm8DXbAhsBGEdxAZjSCuVtkIlsU1c7PJEgDMRuhoRhuJagJECodBTNpOFLWJyIROjklyDcPI-65RV6R4yrq0STucGNGQQFsoaKw1Y0xNF0pM27rIdFFvqv7lp2oQzUqVewilJOG0l3GXhQrZp5rnPqQTHxfpBL5eDxi31x_ruewSaZVfi7W4aqsmX1KuBNIPcmljHeYZ7AlFYdMhA2jARlEVRssu2F7C53NglZrrs2fI1qgE62zGlq2bYh_6VBGJz7LIHLUKXKwFU3EoCTp6sYHdlqatvyvNRQzUuQgqJJTxav67H7HpIdZHpImi4zTr1ZOaesKvZvD6fTp76j_I3_Zw9Lw priority: 102 providerName: ProQuest
Title	Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance study
URI	https://bmjopen.bmj.com/content/15/5/e093366.full https://www.ncbi.nlm.nih.gov/pubmed/40316343 https://www.proquest.com/docview/3201754549 https://www.proquest.com/docview/3199844239 https://pubmed.ncbi.nlm.nih.gov/PMC12049934 https://doaj.org/article/c4dba797dc4c441fb81943b281101663
Volume	15
WOSCitedRecordID	wos001481009000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADZ databaseName: BMJ Journals customDbUrl: eissn: 2044-6055 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000459552 issn: 2044-6055 databaseCode: RMJ dateStart: 20110101 isFulltext: true titleUrlDefault: http://www.bmj.com/thebmj providerName: BMJ Publishing Group Ltd – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2044-6055 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000459552 issn: 2044-6055 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2044-6055 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000459552 issn: 2044-6055 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 2044-6055 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000459552 issn: 2044-6055 databaseCode: M0R dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) customDbUrl: eissn: 2044-6055 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000459552 issn: 2044-6055 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 2044-6055 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000459552 issn: 2044-6055 databaseCode: 7RV dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2044-6055 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000459552 issn: 2044-6055 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 2044-6055 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000459552 issn: 2044-6055 databaseCode: M2M dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2044-6055 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000459552 issn: 2044-6055 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfYQIgXxDeBURmJhyERrY4df_DWdZsYKF1VWFV4iezEUYdGMrVpgf-es5OWFqHxwovl-Etn39l3Jzu_Q-gVKAmTkywGDrAsZAUvQsNsEeZON6rYgMqUPtiEGAzkZKKGG6G-3JuwBh64WbiDjOVGCyXyjGWgugsDKoxRE0ni_E7ucT7B6tlwpvwZzGIVx1ELM0QoPzDfvrp4VEBTxELnxjtcxB0o3VJIHrf_b8bmn28mN5TQyT10t7Ueca-h-j66YcsH6HbS3o8_RN8_6sLWP7EucwwSddm-1cFVgXtfjghoabzfn_bysx8El_1qHBL1GvfPxqdHkMNLnblh3mKNzz_gq2peh3pRT6vZahjtD0c8X8yW1kUrAoHBHp_2ETo_Of7Ufxe2oRVCE7OoDoUGV89QrgzhUhhphc0lYVbHYBHE4DErwjQlwLEuNxktTCGcpSc1l7lixNLHaLesSvsUYWU4sSrXTAGDooIbbahmRndJIbvUiADtwyqn7daYp97roDxtGZI6hqQNQwIUrViRZi1EuYuUcXl9pzfrTlcNQsf1zQ8dj9dNHby2LwChS1uhS_8ldAHaW0nI74lRsKUEGKRMBejluhp2q7uC0aWtFtDG_dLIHOhigJ40ArWmhMH5yimDweWWqG2Rul1TXkw9IjiJnOdK2bP_Mbnn6E7kghy7V53RHtqtZwv7At3KlvXFfNZBO2I0dulE-FR20M3D48Fw1PE7ENKk6_JJlEDN8DQZfoavUfL-F3kzMSQ
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3rb9MwELe2gQAJ8RivwgAjgTQkotWPPIyEUGmZVnXrEGzVxJdgJw4dGklp0479U_yN3OXRUYT6bR_4Fjm2ZTt397u7nO8IeQ4gYWIWufAFZOTIxEscI23ixIiNyjUAmUFRbMLv94OjI_Vhhfyq78JgWGUtEwtBHWcR-si3BCCVD3Av1dvRDwerRuHf1bqERkkWPXt2Cibb5E23A9_3Befb7w_aO05VVcAxruS542uwcozwlGFe4JvA-jYOmLTaBTB0wVhUTGrBYLFNz0QiMYmPSk6gvSBWklkB866SSyDHGYaQ-R8Hc58OqEfKdXmV3IgJb8t8_4ZVsOAkuHTQeYDZGFehdQEGi2oB_1Jx_47U_AP6tm_-b4d2i9yolGzaKrniNlmx6Tq5sleFEayT66WzkpZ3sO6Q0086sfkZ1WlMgRFPqhAnmiW09bnDQLmhm-1hK97_yWjazgYOUy9pe3_Q7cATnekIp31NNT3s0VE2yR09zYfZuJ5GF5hCJ9PxzGKRJ-AzWqT1vUsOL-QY7pG1NEvtA0KV8ZhVsZZKRpInntFGaGl0kyVBUxi_QTaBTMJKokzCwlgTXlhRVIgUFZYU1SC8pqUwqjK7Y4GRk-WDXs0HjcrEJsu7v0MinXfFrORFQzb-GlZCLoxkbLSv_DiCPUmWGFA3pTA8YOgj8kSDbNRker6xcxptkGfz1yDk8M-VTm02hT54E1RirsoGuV9yxHwlEmDJExImDxZ4ZWGpi2_S42GRSJ1xNPiFfLh8XU_J1Z2Dvd1wt9vvPSLXOFaAxpBXvkHW8vHUPiaXo1l-PBk_KcQBJV8umpV-AyanlfI
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1tb9MwELa2gSYkxMt4KwwwEkhDImodOy9GQqi0VFSFbmJsmvgS7MSmQyMpbdqxv8av4y4vHUWo3_aBb1HiWI5zd8_5fL6HkKcAEjphsQd_QMSOsL51tDDWSRAbpacBMsOCbCIYDsOjI7m3Rn7VZ2EwrbK2iYWhTrIYY-RNDkgVANwL2bRVWsRet_d6_MNBBincaa3pNEoRGZizU1i-TV_1u_Cvn7lu7-2nzjunYhhwtCfc3AkUrHg096Vmfhjo0AQmCZkwygNg9GDhKJlQnMHAW76OudU2QIcnVH6YSMEMh37XyaUANwcxbbD1cRHfAVdJep5bFTpi3G_q79-QEQtmxRUOBhKwMuM63F2CxII54F_u7t9Zm3_AYO_6_zyBN8i1yvmm7VJbbpI1k26RzQ9VesEWuVoGMWl5NusWOd1X1uRnVKUJBQU9qVKfaGZp-3OXgdNDdzqjdrL7k9G0kx06TD6nnd3Dfheu6FzF2O1LqujBgI6zae6oWT7KJnU3qsAaOp1N5gbJn0D_aFHu9zY5uJBpuEM20iw19wiV2mdGJkpIEQvX-lpproRWLWbDFtdBg-yAyESVpZlGxSKO-1ElXRFKV1RKV4O4tVxFcVXxHYlHTla_9GLx0rgseLK6-RsU2EVTrFZe3MgmX6PK-EWxSLQKZJDE8E2CWQ1uqODaDRnGjnzeINu1yJ5_2Lm8NsiTxWMwfrijpVKTzaANnhAVWMOyQe6W2rEYiQC48rmAzsMlvVka6vKT9HhUFFhnLgYCuLi_elyPySZoUPS-Pxw8IFdcJIbGTFh3m2zkk5l5SC7H8_x4OnlUWAZKvly0Jv0GUMCejw
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+utilisation+of+AZD1222+%28ChAdOx1+nCoV-19%29+COVID-19+vaccine%3A+a+UK+post-authorisation+active+surveillance+study&rft.jtitle=BMJ+open&rft.au=Miranda+Davies&rft.au=Debabrata+Roy&rft.au=Sandeep+Dhanda&rft.au=Saad+Shakir&rft.date=2025-05-02&rft.pub=BMJ+Publishing+Group&rft.eissn=2044-6055&rft.volume=15&rft.issue=5&rft_id=info:doi/10.1136%2Fbmjopen-2024-093366&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_c4dba797dc4c441fb81943b281101663
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2044-6055&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2044-6055&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2044-6055&client=summon